Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–8 of 8 results
Advanced filters: Author: Jacob S Sherkow Clear advanced filters
  • The CRISPR–Cas9 patent battle demonstrates how overzealous efforts to commercialize technology can damage science, writes Jacob S. Sherkow.

    • Jacob S. Sherkow
    Comments & Opinion
    Nature
    Volume: 532, P: 172-173
  • Predicting the outcome of the ongoing patent disputes surrounding genome-editing technology is equal parts patent analysis and history.

    • Jacob S Sherkow
    Comments & Opinion
    Nature Biotechnology
    Volume: 33, P: 256-257
  • What have we learned from 20 tumultuous years of patent law in the life sciences? Is patenting likely to be as important for the industry in the future?

    • Arti K Rai
    • Jacob S Sherkow
    Comments & Opinion
    Nature Biotechnology
    Volume: 34, P: 292-294
  • Myriad took no prisoners on its way to the top of the molecular diagnostics field. That strategy is unlikely to endure.

    • Jacob S Sherkow
    • Christopher Scott
    Comments & Opinion
    Nature Biotechnology
    Volume: 32, P: 620
  • The Broad Institute's recent licensing of its gene editing patent portfolio demonstrates how licenses can be used to restrict controversial applications of emerging technologies while society deliberates their implications.

    • Christi J Guerrini
    • Margaret A Curnutte
    • Christopher T Scott
    Comments & Opinion
    Nature Biotechnology
    Volume: 35, P: 22-24
  • Choosing an IP protection regime depends on the type of company you are building.

    • Jacob S Sherkow
    Comments & Opinion
    Nature Biotechnology
    Volume: 34, P: 462-465